• Follow us
  • Holding BUMN Farmasi
  • For Healthcare Professional
  • Researcher
  • EN
    Flag IndonesiaID
    Flag EnglishEN
logo-biofarma-2 biofarma-logo
  • About Us
    • Company Profile
      • PT Bio Farma (Persero)
      • Kimia Farma Tbk (KAEF)
      • Indofarma Tbk (INAF)
      • PT INUKI (Persero)
    • History
    • Management
      • Management Team
      • Commisioners
      • Directors
      • Corporate Secretary
    • Our Achievement
      • Awards
      • Certification
    • Report
      • Annual Report
      • Sustainability
  • Product & Service
    • Our Distribution
    • Providers of Health Services & Products
    • Trade, Distribution of Medicines & Medical Devices
  • Media & Information
    • News
      • All News
      • Global Roles
      • Products & Services
      • CSR
    • Health Articles
    • Health FAQ
  • Corporation
    • Good Corporate Governance
    • Our Commitment
    • TJSL
    • LHKPN
      • Lapor
  • Career
    • Why Biofarma
    • Recruitment
    • FAQ
  • PPID
  • Contact Us
search

Good Corporate Governance

In order to build good corporate governance, the Company shall have a commitment, consistent, and persistent from all relevant parties, i.e : all management levels, Employees, Board of Commissioners, Government and other Stakeholders.

  • Good Corporate Governance
  • Quality Assurance Control
  • Responsibilty to Customer
  • Corporate Governance Implementation Process
  • Gratification Control Process
  • Process of Whistle Blowing System
  • Guidelines for The Board of Commisioner and Director
  • Biofarma Code of Conduct
  • Guidelines for Handling Conflict of Interest
  • Charter
    • Internal Audit Charter
    • AUDIT COMMITTEE CHARTER
    • Risk Committee Charter
  • Risk Management
  • Directors Guidelines
  • Audit Committee
  • Development Risk and GCG Committee
  • Superior Performance Assessment Criteria
Select Menu

The Whistleblowing System is regulated in the Joint Regulation of the Board of Commissioners and Directors of PT Bio Farma (Persero) Number: PER-08/DK/BF/12/2018; Number: PER-06965/DIR/XII/2018 dated December 31, 2018 concerning the Code of Conduct.

Whistleblowers can report online through a web-based system with the address

http://aplikasi.biofarma.co.id/gcg

The mechanism for reporting violations (Whistleblowing System) is as follows:

Image

In the event of a violation of the Code of Conduct, Bio Farma personnel are obliged to report to:

  1. The immediate superior concerned where each superior is obliged to give full attention to the report of Bio Farma personnel who are subordinates and try to resolve it thoroughly in accordance with the applicable provisions in the Company. If a Bio Farma Personnel is unable to report to his/her immediate superior due to a Conflict of Interest with his/her superior, he/she may discuss the matter with the following parties:
  • The superior of the direct supervisor concerned;
  • HR Division;
  • Compliance & Risk Management Division; or
  • Labor Union;
  1. Whistleblowing System.

In addition to internal parties of the Company, the Whistleblowing System can also be carried out by external parties of the Company such as Customers, Business Partners, and other Stakeholders.

Reporting must be done in good faith and not based on bad will / slander.

Whistleblowers in submitting Whistleblowing can include personal data identity containing home / office address, e-mail address, facsimile, contact number that can be contacted or may not include personal data (anonymous);

Reporting must be accompanied by supporting evidence, including:

  1. The subject matter of the complaint;
  2. Parties involved in the violations complained of, including those who were harmed/benefited from the case;
  3. Chronology of the case; and
  4. Other supporting documents for the case.

The Company provides protection to whistleblowers as follows:

Protection of confidentiality of the Whistleblower's identity;

  1. Protection of the confidentiality of the Whistleblower's identity;
  2. Protection against retaliation from the reported party;
  3. Protection from dismissal, demotion or band, delayed 

promotion, pressure, and physical action;

  1. Protection of adverse records in their personal data files (personal file records);
  2. Information regarding the follow-up process that is being carried out (to Whistleblowers who provide personal data). This information is delivered confidentially to the Whistleblower.
  • The implementation of verification by the whistleblowing manager is carried out within 30 (thirty) working days and can be extended for a maximum of the next 30 (thirty) working days.
  • The implementation of the investigation by the Investigation Team on the violation reporting received is carried out within 30 (thirty) working days and can be extended for a maximum of the next 30 (thirty) working days.

For reporters who clearly state their personal data, the reporter will receive information regarding the handling of the case they reported, whether it can be followed up or not.

  WBS-BUKU-SAKU

  • Good Corporate Governance
  • Quality Assurance Control
  • Responsibilty to Customer
  • Corporate Governance Implementation Process
  • Gratification Control Process
  • Process of Whistle Blowing System
  • Guidelines for The Board of Commisioner and Director
  • Biofarma Code of Conduct
  • Guidelines for Handling Conflict of Interest
  • Charter
    • Internal Audit Charter
    • AUDIT COMMITTEE CHARTER
    • Risk Committee Charter
  • Risk Management
  • Directors Guidelines
  • Audit Committee
  • Development Risk and GCG Committee
  • Superior Performance Assessment Criteria

Logo biofarma

Call Center 1500810
Head Office
Jl. Pasteur No. 28, Bandung 40161,
Jawa Barat Indonesia
+62 22-2033755
+62 22 - 2041306
mail@biofarma.co.id

Breeding Facility Bio Farma
Jl. Kolonel Masturi Kav 10. Desa Kertawangi kec. Cisarua
Jawa Barat
Bio Farma Representative Office
Gd. Pakarti centre Lantai 7
Jln. Tanah Abang 3 no.23-27
Jakarta Pusat

Digital Healthcare Office Jakarta Lt. 26
Equity Tower Sudirman Central Business District (SCBD) Lot 9
Jl. Jend. Sudirman Kav. 52-53
Jakarta Selatan 12190, Indonesia
Information
  • Good Corporate Governance
  • Our Procurement
  • FAQ
  • Vaccine Production
  • Your Career
 
  • Contact Us
  • E-PPID
  • Announcement
  • I Want to
  • Media Release
Our Partner

Quick Links
  • Portal BUMN-Bio
  • Kemenkes RI
Copyright © 2023. All Rights Reserved by Bio Farma
Holding BUMN Farmasi
For Healthcare Professional
Researcher

Change Language

EN
  • About Us
    • Company Profile
      • Company Profile
      • PT Bio Farma (Persero)
      • Kimia Farma Tbk (KAEF)
      • Indofarma Tbk (INAF)
      • PT INUKI (Persero)
    • History
    • Management
      • Management Team
      • Commisioners
      • Directors
      • Corporate Secretary
    • Our Achievement
      • Awards
      • Certification
    • Report
      • Annual Report
      • Sustainability
  • Product & Service
    • Our Distribution
    • Providers of Health Services & Products
    • Trade, Distribution of Medicines & Medical Devices
  • Media & Information
    • News
      • All News
      • Global Roles
      • Products & Services
      • CSR
    • Health Articles
    • Health FAQ
  • Corporation
    • Good Corporate Governance
    • Our Commitment
    • TJSL
    • LHKPN
      • Lapor
  • Career
    • Career
    • Why Biofarma
    • Recruitment
    • FAQ
  • PPID
  • Contact Us
  • Follow us
Change Language
  • Flag IndonesiaID
  • Flag EnglishEN